Cell Rep 2020 Feb 9; 34(6):108739
Genetic and genome-wide association studies suggest a central role for microglia in Alzheimer's disease (AD). However, single-cell RNA sequencing (scRNA-seq) of microglia in mice, a key preclinical model, has shown mixed results regarding translatability to human studies. To address this, scRNA-seq of microglia from C57BL/6J (B6) and wild-derived strains (WSB/EiJ, CAST/EiJ, and PWK/PhJ) with and without APP/PS1 demonstrates that genetic diversity significantly alters features and dynamics of microglia in baseline neuroimmune functions and in response to amyloidosis. Results show significant variation in the abundance of microglial subtypes or states, including numbers of previously identified disease-associated and interferon-responding microglia, across the strains. For each subtype, significant differences in the expression of many genes are observed in wild-derived strains relative to B6, including 19 genes previously associated with human AD including Apoe, Trem2, and Sorl1. This resource is critical in the development of appropriately targeted therapeutics for AD and other neurological diseases.
Yang, Hongtian Stanley; Onos, Kristen D.; Choi, Kwangbom; Keezer, Kelly J; Skelly, Daniel A; Carter, Gregory W.; and Howell, Gareth R, "Natural genetic variation determines microglia heterogeneity in wild-derived mouse models of Alzheimer's disease." (2021). Faculty Research 2021. 43.